US · Healthcare · Diagnostics & Research
EPS came in at 0.62 against a street estimate of 0.60 — a beat of 3.3%.
Analysts rate Qiagen NV a buy (9 buy, 7 hold, 0 sell out of 16) with an average price target of $46.27.
CONFIDENT QGEN beat Q2 outlook on sales and EPS, reaffirming full-year guidance. Growth pillars (Sample Tech +9%, QIAcuity double-digit, QDI solid) offsetting QuantiFERON immigration testing headwinds. H2 acceleration expected from new launches and easier comps. Q2 2026 Mixed regional performance; sequential improvement in China and ex-China Asia-Pacific gaining momentum. Analysts pressed on QuantiFERON tariffs, funding headwinds, and automation timelines. Management defended with TAM expansion, TST conversion thesis, and product validation justifying timelines; maintained strategic-review optionality without timeline. 2026-08-06…
Full summary in the app.
| Fund | Stake |
|---|---|
| Wellington Management Company LLP | 6.01% |
| T. Rowe Price Associates, Inc. | 4.08% |
| Principal Financial Group Inc | 3.22% |
| Vanguard Capital Management, LLC | 2.96% |
| Deutsche Bank AG | 2.71% |
| BlackRock Inc | 2.54% |
| Amundi | 2.30% |
| NORGES BANK | 2.09% |
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.35 / share ex-date Jul 7, 2026 · pay Jul 14, 2026 | 2026-07-07 |
| Dividend | $2.41 / share ex-date Jan 8, 2026 | 2026-01-08 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Qiagen NV — free to start.
Google PlayApp StoreData updated 2026-09-18.